CTOs on the Move

AmnioLife

www.amniolife.com

 
AmnioLife Corporation is a biotechnology company focused on the development and commercialization of a unique biologic suite of products designed to address unmet and underserved market needs with applications across multiple surgical specialties. We are committed to the development of novel biotechnology and regenerative therapeutics, primarily derived from placental origin. Currently we have filed a US provisional patent application on our core technology, ProLifixTM, an acellular collagen matrix. The Company has over 60 years of experience in biologics manufacturing and comercializaiton, and is led by Chris Broderick who recently launched a neurological tissue transplant technology and was responsible for over $10M in ...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

GeneData

GeneData is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Groton Biosystems

Groton Biosystems is a Boxborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Catheter Connections

Catheter Connections is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eurofins

Eurofins is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Be Biopharma

Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.